Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Toxicopathology of the Developing Immune System: Investigative and Development Strategies TOXICOLOGIC PATHOLOGY Weinstock, D., Lewis, D. B., Parker, G. A., Beyer, J., Collinge, M., Brown, T. P., Dybdal, N. 2010; 38 (7): 1111-1117

Abstract

Developmental immunotoxicity (DIT) has gained attention with the recognition that environmental chemicals can potentially affect the developing immune system and the incidence of childhood allergic diseases. Preclinical safety assessment of pharmaceuticals for men and women of childbearing potential as well as for pediatric and juvenile indications may require DIT assessments. Draft documents from environmental and chemical regulatory agencies propose strategies that use the rat as a test species and incorporate histopathology and functional testing as endpoints. While there are no guidelines for DIT assessment of pharmaceuticals, current discussions suggest that combining immunotoxicity and developmental and reproductive toxicology studies may serve this purpose. Knowledge of the principles and applications of DIT will facilitate participation in strategy development and effective conduct of relevant studies.

View details for DOI 10.1177/0192623310382436

View details for Web of Science ID 000293378600011

View details for PubMedID 20962107